2008-07-04 20:35:17 - www.companiesandmarkets.com adds new report - Introgen Therapeutics Inc - Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/Introgen-The ..
Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of pipeline candidates using its ‘Enabling Technologies’.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial

trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

The company’s product candidates include includes five clinical-stage product candidates: ADVEXIN and INGN 241 in Phase III clinical trials for head and neck cancer; INGN 225, a therapeutic p53 vaccine, in Phase II clinical development for lung and breast cancer.



The company´s INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, in Phase I clinical development; and INGN 401, a systemic nanoparticle tumor suppressor is in Phase II clinical trials for metastatic lung cancer.



The company recognizes revenues in the form of contract research fees from other pharmaceutical/biotechnology companies, and grants from academic and government organizations. The company’s total revenues have slightly declined at a CAGR of 0.5% during 2002-2006, almost flat at $1.2 million.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company’s adjusted five year financial data along with key ratios and market capitalization